This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Christine Van Broeckhoven | |
|---|---|
| Name | Christine Van Broeckhoven |
| Birth date | 1953 |
| Birth place | Leuven, Belgium |
| Nationality | Belgian |
| Fields | Genetics, Neuroscience, Molecular Biology |
| Institutions | University of Antwerp, University of Leuven, Flanders Institute for Biotechnology |
| Alma mater | Katholieke Universiteit Leuven |
| Known for | Genetic research on Alzheimer's disease and neurodegeneration |
Christine Van Broeckhoven Christine Van Broeckhoven is a Belgian molecular geneticist and neuroscientist known for pioneering work on the genetic basis of Alzheimer's disease and other neurodegenerative disorders. She has held professorships and laboratory directorships in Belgian institutions and contributed to international consortia, collaborative projects, and translational initiatives linking academic research with clinical neurology and biotechnology sectors.
Van Broeckhoven was born in Leuven and completed early studies at local schools before enrolling at Katholieke Universiteit Leuven, where she earned degrees in biochemistry and molecular biology. During doctoral research she trained in genetics laboratories influenced by European centers such as University of Antwerp collaborators and visited groups in Paris, London, and Leiden to study protein chemistry and gene mapping. Her postgraduate training placed her in networks connected to researchers at Max Planck Society, Institut Pasteur, University College London, and the Karolinska Institutet, fostering ties with investigators working on Alzheimer's disease, Huntington's disease, Parkinson's disease, and familial dementia syndromes.
Van Broeckhoven established a research program integrating molecular genetics, linkage analysis, and neuropathology, affiliating with institutions including University of Antwerp, Katholieke Universiteit Leuven, and the Flanders Institute for Biotechnology. She collaborated with clinicians from University Hospital Antwerp, neurologists associated with University Hospitals Leuven, and consortia like the European Alzheimer's Disease Consortium and the Alzheimer's Disease Genetics Consortium. Her laboratory employed techniques developed at places such as Harvard Medical School, Massachusetts Institute of Technology, Stanford University, and Cold Spring Harbor Laboratory and engaged with biotechnology companies like Genentech, Novartis, GlaxoSmithKline, and Roche on translational studies. She trained doctoral and postdoctoral researchers who subsequently joined faculties at University of Oxford, University of Cambridge, Imperial College London, McGill University, and Utrecht University.
Van Broeckhoven contributed to the identification and characterization of genetic mutations associated with familial forms of Alzheimer's disease and frontotemporal dementia, working on loci and genes also investigated by teams at Mayo Clinic, Johns Hopkins University, Columbia University, and University of California, San Francisco. Her work intersected with discoveries related to APP, PSEN1, PSEN2, and MAPT by groups at Washington University in St. Louis, Mount Sinai School of Medicine, University of Toronto, and Karolinska Institutet. She helped map risk alleles and modifier genes, contributing data to projects coordinated with the Human Genome Project, the 1000 Genomes Project, and initiatives like the International HapMap Project and the European Biobank Network. Her publications were cited alongside reports from Nature Genetics, Science, The Lancet Neurology, and Neuron, and her datasets were integrated into resources maintained by the European Molecular Biology Laboratory, Ensembl, and the National Center for Biotechnology Information. Van Broeckhoven's translational efforts informed biomarker studies linked to cohorts from Framingham Heart Study, Rotterdam Study, and memory clinic networks across Belgium and The Netherlands.
Van Broeckhoven has received national and international recognition including awards and memberships associated with Royal Academy of Belgium, Belgian Royal Society, and honors conferred by universities such as University of Antwerp and Katholieke Universiteit Leuven. She was invited to lecture at conferences organized by Society for Neuroscience, Alzheimer Europe, European Federation of Neurological Societies, and editorial roles with journals connected to Springer Nature and Elsevier. Professional fellowships and distinctions linked her to academies like the Academia Europaea, the Royal Flemish Academy of Belgium for Science and the Arts, and national research funding agencies including Research Foundation – Flanders and the European Research Council.
Van Broeckhoven engaged in science policy and public communication, advising governmental bodies and participating in committees linked to European Commission research programs, national health agencies, and patient advocacy organizations like Alzheimer Europe and local chapters of Alzheimer's Association. She contributed expertise to initiatives at institutions such as Belgian Ministry of Health, Flemish Parliament, and municipal health programs in Antwerp. Her outreach connected research, clinical practice, and biotech policy discussions involving stakeholders from European Medicines Agency, World Health Organization, and industry partners.
Van Broeckhoven's personal background includes ties to academic families in Leuven and professional networks spanning Antwerp, Brussels, and international centers including Cambridge, New York City, and Stockholm. Outside the laboratory she has participated in public lectures at venues such as Royal Flemish Theatre events and contributed to science communication platforms in collaboration with broadcasters like VRT and BBC.
Category:Belgian geneticists Category:Belgian neuroscientists Category:Women geneticists